Online inquiry

IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3710MR)

This product GTTS-WQ3710MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MSLN gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001177355.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10232
UniProt ID Q13421
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3710MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ754MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AAB-001
GTTS-WQ14179MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-910
GTTS-WQ3472MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ4345MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIW-8405
GTTS-WQ2219MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aVWF81
GTTS-WQ11662MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ7174MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ10073MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA L19TNF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW